Dacomitinib (dacomitinib) price after inclusion in medical insurance in 2024

Dacomitinib (Dacomitinib), trade name Vizimpro, is an oral, irreversible second-generation EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor (TKI). It is primarily used to treat patients with metastatic non-small cell lung cancer (NSCLC) who harbor specific EGFR mutations. Dacomitinib (Dacomitinib) was developed to overcome the resistance issues that arise during first-generation EGFR-TKI treatment, such as the common EGFR T790M mutation.

Dacomitinib is now available in China and has been included in the medical insurance directory, and patients can purchase it domestically. The specifications of this medicine are 15 mg and 30 tablets, and the price is about more than 1,000 yuan. For specific price information and medical insurance reimbursement related matters, please consult the local hospital pharmacy. In comparison, the European version of Pfizer's original drug is more expensive, about more than 20,000 yuan. In the foreign market, the price is relatively affordable for generic drugs from Laos. Its specifications are 45mg and 30 tablets. The price is three times lower than the domestic price in multiples, and its drug ingredients are basically the same as the original drug.

Dacomitinib blocks the EGFR signaling pathway by irreversibly binding and inhibiting EGFR tyrosine kinase activity, thereby inhibiting the growth and proliferation of tumor cells. It has a strong inhibitory effect on a variety of EGFR mutations, including L858R and Exon 19 deletion mutations, which are common in NSCLC. Dacomitinib's irreversible binding mode makes it more durable in inhibiting EGFR activity and prolongs progression-free survival (PFS).

In the clinical trialARCHER 1050,dacomitinib showed superiority to first-generationEGFR-TKIEfficacy of gefitinib. The trial results showed that the median progression-free survival in the dacomitinib (dacomitinib) treatment group was 14.7 months, compared with 9.2 months in the gefitinib group. In addition, dacomitinib also prolonged patients’ overall survival (OS ). These results led to the approval of Dacomitinib by the U.S. Food and Drug Administration (FDA) in 2018 for the first-line treatment of patients with metastatic NSCLC harboring EGFR mutations.

However,dacomitinib is also associated with a higher incidence of adverse reactions. The most common adverse reactions include rash, diarrhea, stomatitis, paronychia, and abnormal liver function. Because these adverse reactions may affect the patient's quality of life, they require careful monitoring and management during treatment, with dose adjustment or temporary discontinuation if necessary.